Waters Corporation. (1/15/19). "Press Release: Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System". Milford, MA.

	Organisation	Waters Corporation (NYSE: WAT)
	Group	Waters (Group)
	Organisation 2	Pfizer Inc. (NYSE: PFE)
	Group	Pfizer (Group)
	Product	BioAccord™ LC-MS System
	Product 2	ACQUITY RDa™ Detector featuring SmartMS™
	Person	O’Connell, Christopher J. (Chris) (Waters 201509–202009 CEO before over 21 years at Medtronic)
	Person 2	Tarmy, Jeff (Waters 201005)

As the Number of Analytical Monitoring Tests for Biopharmaceuticals Skyrockets, Waters Builds Intelligence into a Fit-for-Purpose System

Waters Corporation (NYSE:WAT) today introduced the BioAccord™ System, a purposefully designed liquid chromatography-mass spectrometry (LC-MS) solution that will expand access to high-resolution time-of-flight mass spectrometry capabilities to more scientists. The BioAccord System promises to move routine monitoring out of centralized MS labs and into the hands of more scientists by enabling more effective analysis of biotherapeutic protein attributes across development and within quality control organizations.

"The pace of innovation in the biopharmaceutical industry is accelerating, and with it, the monitoring requirements for biotherapeutics are growing exponentially," said Chris O'Connell, Chairman and CEO, Waters Corporation. "The inherent complexity of these therapies, combined with rising regulatory standards, are driving more intensive and widespread testing requirements. Waters designed the BioAccord System as a fit-for-purpose LC-MS biopharmaceutical solution to deliver rich mass spectrometry data for improved productivity and effective decision-making."

The BioAccord System pairs ACQUITYTM UPLC™ I-Class Plus with the newly-developed ACQUITY RDa™ Detector featuring SmartMS™. This system offers new levels of user experience with automated setup and self diagnosis delivered through an intuitive user interface, all within a surprisingly small footprint. Powered by UNIFI™, Waters’ compliance-ready LC-MS informatics platform, the BioAccord System has been optimized for intact protein, released glycan, and peptide monitoring applications, and streamlined by the use of Waters' application-specific chemistries and consumables kits.

The first public exhibition of the BioAccord System will take place at the Well Characterized Biopharmaceutical Conference (WCBP) in Washington D.C. On Tuesday, January 29, at WCBP, Waters will sponsor a lunch seminar in the Palm Court Room at the Mayflower Hotel from 12:45 – 1:45 p.m. titled: High Performance LCMS Analysis in Biopharma: From Molecular Characterization to Routine Monitoring featuring Dr. John Gebler, Director, Biopharmaceutical, Waters Corporation. Guest speaker, Dr. Mellisa M. Ly, Principal Scientist from Pfizer, Inc. will expand on the topic presenting, Characterizing and Monitoring Quality Attributes in Monoclonal Antibodies using a High Resolution, Small Footprint LC-MS System.

Additionally, customers are invited to visit www.waters.com/bioaccord for a deeper understanding of the new BioAccord LC-MS system.

The BioAccord System is currently available for customer shipments worldwide.

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With approximately 7,000 employees worldwide, Waters operates directly in 31 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Jeff Tarmy
508-482-2268
jeff_tarmy@waters.com

Record changed: 2019-01-29